Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy Clinical research trials and Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy. Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.

Home > "B" Clinical Trials Conditions > Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy

Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy



Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy

For Condition: recurrent adult diffuse large cell lymphoma
Status: Recruiting
Sponsor(s): Jonsson Comprehensive Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who have diffuse large B-cell lymphoma that is refractory to previous chemotherapy.
Details: OBJECTIVES: - Determine the overall response rate in patients with chemotherapy-refractory diffuse large B-cell lymphoma treated with bortezomib. - Determine the safety and tolerability of this drug in these patients. - Determine the time to disease progression in patients treated with this drug. - Determine the possible mechanism of resistance to this drug in these patients. OUTLINE: This is an open-label, multicenter study. Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients are followed at 20 days and then every 3 months thereafter. PROJECTED ACCRUAL: A total of 22-40 patients will be accrued for this study.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed diffuse large B-cell lymphoma, meeting criteria for 1 of the following: - Relapsed after prior high-dose chemotherapy with stem cell support - Relapsed after prior chemotherapy, including at least 1 prior standard non-Hodgkin’s chemotherapy regimen, but not a candidate for high-dose chemotherapy with stem cell support - Measurable disease - At least 1 bidimensionally measurable lesion at least 1.5 cm by CT scan - No primary or secondary CNS lymphoma - No HIV-related lymphoma - No known brain metastases PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-2 OR - Karnofsky 60-100% Life expectancy - More than 3 months Hematopoietic - Hemoglobin at least 9 g/dL - Absolute neutrophil count at least 1,000/mm - No colony-stimulating factors within 4 weeks before obtaining this result - Platelet count at least 50,000/mm - No platelet transfusion within 4 weeks before obtaining this result Hepatic - Bilirubin no greater than 2 times upper limit of normal (ULN) - AST and ALT no greater than 2.5 times ULN - No active hepatitis B or C viral infection Renal - Creatinine no greater than 2 times ULN OR - Creatinine clearance at least 60 mL/min Cardiovascular - No myocardial infarction within the past 6 months - No evidence of acute ischemia or new conduction system abnormalities on EKG - No symptomatic congestive heart failure - No unstable angina pectoris - No cardiac arrhythmia Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - Sodium greater than 130 mEq/L - HIV negative - No ongoing or active infection - No other concurrent uncontrolled illness that would preclude study participation - No psychiatric illness or social situation that would preclude study compliance - No prior allergic reaction attributable to compounds of similar chemical or biological composition to bortezomib PRIOR CONCURRENT THERAPY: Biologic therapy - See Disease Characteristics - See Chemotherapy - At least 4 weeks since prior immunotherapy Chemotherapy - See Disease Characteristics - More than 4 weeks since prior chemotherapy - More than 12 weeks since prior high-dose chemotherapy with hematopoietic stem cell support Endocrine therapy - No concurrent corticosteroids Radiotherapy - More than 4 weeks since prior radiotherapy - No concurrent radiotherapy Surgery - More than 4 weeks since prior major surgery unless fully recovered Other - Recovered from prior therapy - No other concurrent investigational agents - No other concurrent investigational or commercial agents or therapies to treat the malignancy
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
SvenVos,  Study Chair,  Jonsson Comprehensive Cancer Center

Jonsson Comprehensive Cancer Center, UCLA *Recruiting*
Los Angeles,  California,  90095
United States
Recruiting Sven  Vos 310-825-4796


Additional Information:
Study ID Numbers:  CDR0000316254;  UCLA-0301090
Study Start Date: 
Record last reviewed: July 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00066508

Other Recurrent Adult Diffuse Large Cell Lymphoma Studies:
1. Radiation Therapy and Cyclophosphamide Plus Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma

2. Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer

3. Rituximab and Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

4. Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

5. Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Related Studies:

Other recurrent adult diffuse large cell lymphoma Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials

Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy
Modify your Search

  Other recurrent adult diffuse large cell lymphoma Clinical Trials
  Other California Clinical Trials
  Other Los Angeles Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103